[1] 中华医学会肝病学分会,中华医学会感染病学分会. 丙型肝炎防治指南(2015更新版),中华传染病杂志,2015,33:705-724.
[2] Nishida N, Iwanishi M, Minami T, et al. Early viral response predicts the efficacy of antiviral triple therapy with Simeprevir, Peg-Interferon and Ribavirin in patients infected with hepatitis C virus genotype 1. Dig Dis, 2015, 33:708-714.
[3] Yee BE, Nguyen NH, Zhang B, et al. Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2 and 3: a meta-analysis. BMJ Open Gastroenterol, 2015, 2:e000049.
[4] 陈铿,张爱民,谢敏,等. 聚乙二醇干扰素α-2a 与聚乙二醇干扰素α-2b 治疗慢性乙型肝炎疗效对比分析. 临床消化病杂志,2013,25:174-175.
[5] Miyase SI, Haraoka K, Ouchida Y, et al. Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients. J Gastroenterol, 2012, 47:1014-1021.
[6] Bennett H, Waser N, Johnston K, et al. A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan, Hepatol Int, 2015, 9:378-390.
[7] Kumthip K, Chusri P, Pantip C, et al. Analysis of mutations in the core and NS5A genes of hepatitis C virus in non-responder and relapser patients after treatment with Peg-IFN-α and ribavirin. Virusdisease, 2016, 27: 55-62.
[8] 朱研,毛青,张长江,等. 聚乙二醇干扰素α-2a/2b联合利巴韦林复治慢性丙型肝炎患者的疗效观察. 临床肝胆病杂志,2011,27:86-88.
[9] 侯玉香,雷兴琼,任江南,等. 聚乙二醇干扰素α-2a 及聚乙二醇干扰素α-2b 治疗慢性乙型肝炎临床研究. 胃肠病学和肝病学杂志,2012,21:646-648.
[10] Witthoeft T, Hueppe D, John C, et al. Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE study. J Viral Hepat. 2010, 17:459-468.
[11] Berak H, Laskus T, Kolakowska-Rzadzka A, et al. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study. Adv Med Sci, 2014, 59: 261-265.
[12] Hauser G, Awad T, Thorlund K, et al. Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C. Cochrane Database Syst Rev, 2014, 28: CD005642. |
